We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+1%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$65.2B
AUM Growth
+$6.51B
(+11%)
Cap. Flow
+$6.71B
Cap. Flow
% of AUM
10.29%
Top 10 Holdings %
Top 10 Hldgs %
15.4%
Holding
2,716
New
313
Increased
1,389
Reduced
876
Closed
123
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$213M |
| 2 |
Cigna
CI
|
+$207M |
| 3 |
Comcast
CMCSA
|
+$164M |
| 4 |
Zoom
ZM
|
+$155M |
| 5 |
Johnson & Johnson
JNJ
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$237M |
| 2 |
TSMC
TSM
|
+$214M |
| 3 |
NVIDIA
NVDA
|
+$138M |
| 4 |
Adobe
ADBE
|
+$133M |
| 5 |
Pultegroup
PHM
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.59% |
| 2 | Financials | 13.87% |
| 3 | Industrials | 12.52% |
| 4 | Consumer Discretionary | 12.44% |
| 5 | Healthcare | 12.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Protalix BioTherapeutics
PLX
$200M
| $66.8K | ﹤0.01% |
+57,106
| New | +$67.5K |
|
2527
Savara
SVRA
$1.17B
| $66.4K | ﹤0.01% |
16,483
-4,709
| -22% | -$21K |
|
|
BIG
2528
DELISTED
Big Lots, Inc.
BIG
| $66.1K | ﹤0.01% |
38,198
-20,708
| -35% | -$66.9K |
|
2529
PDS Biotechnology
PDSB
$40.9M
| $64.9K | ﹤0.01% |
22,156
+1,300
| +6% | +$4.16K |
|
2530
Allogene Therapeutics
ALLO
$725M
| $63.6K | ﹤0.01% |
+27,287
| New | +$80.5K |
|
2531
KVH Industries
KVHI
$148M
| $63.4K | ﹤0.01% |
+13,643
| New | +$68K |
|
|
KLRS
2532
Kalaris Therapeutics
KLRS
$93.7M
| $62K | ﹤0.01% |
3,729
-347
| -9% | -$6.13K |
|
2533
FTC Solar
FTCI
$46.8M
| $61.8K | ﹤0.01% |
17,502
-70,904
| -80% | -$335K |
|
|
BGXX
2534
DELISTED
Bright Green Corporation Common Stock
BGXX
| $59.7K | ﹤0.01% |
235,575
+209,337
| +798% | +$51.9K |
|
2535
Information Services Group
III
$251M
| $56.9K | ﹤0.01% |
+19,340
| New | +$65K |
|
2536
Fate Therapeutics
FATE
$322M
| $54K | ﹤0.01% |
16,460
-5,638
| -26% | -$24.7K |
|
2537
MaxCyte
MXCT
$130M
| $52.9K | ﹤0.01% |
13,489
-1,906
| -12% | -$8.2K |
|
2538
Traeger
COOK
$172M
| $52.1K | ﹤0.01% |
+435
| New | +$50.2K |
|
2539
ProKidney
PROK
$347M
| $50.5K | ﹤0.01% |
+20,518
| New | +$55.1K |
|
|
ALTM
2540
DELISTED
Arcadium Lithium plc
ALTM
| $50K | ﹤0.01% |
+14,895
| New | +$62.2K |
|
2541
Microvast
MVST
$291M
| $49.8K | ﹤0.01% |
109,139
+92,828
| +569% | +$41.7K |
|
2542
NovaGold Resources
NG
$3.35B
| $49.3K | ﹤0.01% |
+14,249
| New | +$47.3K |
|
2543
Tredegar Corp
TG
$292M
| $48.7K | ﹤0.01% |
+10,163
| New | +$59.3K |
|
2544
CorMedix
CRMD
$591M
| $48.4K | ﹤0.01% |
11,189
-12,641
| -53% | -$64.2K |
|
|
INZY
2545
DELISTED
Inozyme Pharma
INZY
| $48.2K | ﹤0.01% |
10,807
-16,909
| -61% | -$82K |
|
|
SRG
2546
Seritage Growth Properties
SRG
$136M
| $47.6K | ﹤0.01% |
+10,198
| New | +$74K |
|
2547
Tenaya Therapeutics
TNYA
$165M
| $43.3K | ﹤0.01% |
13,978
-4,936
| -26% | -$20.4K |
|
2548
Zura Bio
ZURA
$535M
| $43.1K | ﹤0.01% |
+12,319
| New | +$50.2K |
|
2549
Finance of America Companies
FOA
$195M
| $41.3K | ﹤0.01% |
+8,370
| New | +$51K |
|
2550
Hyliion Holdings
HYLN
$701M
| $40K | ﹤0.01% |
+24,703
| New | +$36.7K |
|
Similar funds
VGA
AQR Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, AQR Capital Management held 2,716 positions worth $65.2B, up 11% from $58.7B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
AQR Capital Management deployed $6.71B of net new capital in Q2 2024, opening 313 new positions and adding to 1,389 existing holdings. Its largest new stake was Solventum: 1,217,998 shares worth $62.6M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Humana, an estimated $237M trimmed.
- AQR Capital Management's largest Q2 2024 buy was Solventum: 1,217,998 shares worth $62.6M.
- AQR Capital Management added most to ExxonMobil in Q2 2024, an estimated $213M increase.
- AQR Capital Management's biggest Q2 2024 reduction was Humana, cutting an estimated $237M.
- AQR Capital Management fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $27.7M.
- AQR Capital Management's ten largest holdings make up 15% of its $65.2B portfolio in Q2 2024.
- AQR Capital Management opened 313 new positions and closed 123 in Q2 2024.
- AQR Capital Management's portfolio value rose 11% quarter-over-quarter to $65.2B.
Based on AQR Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.